Shares of penny stock Aethlon Medical , which trades over the counter, ran up 29% in premarket trade Tuesday, after the company announced the first use of its Hemopurifier therapy on a patient infected with Ebola. The treatment was made to a Ugandan, World Health Organization doctor in Frankfurt, Germany, who contracted the virus in Sierra Leone. Aethlon's Hemopurifier targets the elimimation of viruses and cancer-related proteins from the circulatory system of infected patients. Aethlon said it was preparing to initiate U.S. clinical studies of its Hemopurifier device, which has received an investigational device exemption from the Food and Drug Administration.
Copyright © 2014 MarketWatch, Inc.
Continue Reading Below